1Muller T, Hefter H, Hueber R, et al. Is levodopa toxic? J Neurol, 2004, 251 (suppl 6):Ⅵ/44-46.
2Corona-Morales AA, Castell A, Escobar A, et al. Fullerene C60 and ascorbic acid protect cultured chromaffin cells against levodopa toxicity. J Neurosci Res, 2003, 71 ( 1 ) : 121-126.
3Zeng BY, Pearce RK, MacKenzie GM, et al. Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1 , D-2 or D-3 receptor in the striatum of normal monkeys : an autoradiographic study. J Neural Transm, 2001 , 108 ( 8-9 ) :925-941.
4Datla KP, Blunt SB, Dexter DT. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl3 nigrostriatal lesions. Mov Disord, 2001, 16(3) : 424-434.
5Mytilineou C, Walker RH, JnoBaptiste R, et al. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther, 2003, 304(2) : 792-800.
6Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA, 2002, 287(13) : 1653-1661.
7Whone A, Watts R, Stoessl J, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa : the REALPET Study. Ann Neurol, 2003, 54(1) : 93-101.
8Fahn S, Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol,2005, 252( suppl 4) : iv37-iv42.
9Verhagen Metman L. Recognition and treatment of response fluctuations in Parkinson's disease. Amino Acids, 2002, 23 ( 1 -3) : 141-145.
10Lee CR, Abercrombie ED, Tepper JM. Pallidal control of substantia nigra dopaminergic neuron firing pattern and its relation to extracellular neostriatal dopamine levels. Neuroscience, 2004,129(2) : 481-489.
